Rolando M Viani1, Theodore Ruel2, Carmelita Alvero3, Terry Fenton3, Edward P Acosta4, Rohan Hazra5, Ellen Townley6, Paul Palumbo7, Ann M Buchanan8, Cindy Vavro8, Rajendra Singh8, Bobbie Graham9, Patricia Anthony10, Kathleen George11, Andrew Wiznia12. 1. Department of Pediatrics, University of California, San Diego and Rady Children's Hospital San Diego, La Jolla. 2. Division of Pediatric Infectious Diseases and Global Health, Department of Pediatrics, University of California, San Francisco. 3. Statistical and Data Analysis Center, Harvard School Public Health, Boston, Massachusetts. 4. University of Alabama at Birmingham. 5. Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland. 6. Columbus Technologies and Services, Contractor to the Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland. 7. Division of Infectious Diseases, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire. 8. ViiV Healthcare, Research Triangle Park, North Carolina. 9. Frontier Science Inc, Buffalo, New York. 10. University of Southern California, Los Angeles. 11. FHI 360, Durham, North Carolina. 12. Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York.
Abstract
BACKGROUND: P1093 is an ongoing phase I/II multicenter open-label study of dolutegravir plus an optimized background regimen in age-defined pediatric cohorts; here we report the long-term safety and virologic efficacy outcomes for the oldest cohort. METHODS: The study enrolled human immunodeficiency virus type 1 (HIV-1)-infected treatment-experienced adolescents aged 12 to <18 years, with an HIV-1 RNA level ≥1000 copies/mL . Cumulative safety and HIV-1 RNA outcomes were assessed once the last enrolled participant reached 144 weeks of follow-up. RESULTS: Among 23 adolescents enrolled, 16 remained in the study at least 144 weeks; the median follow-up was 153 weeks (range, 55-193 weeks). Dolutegravir was well tolerated, with grade 3 clinical adverse events in 5 participants, grade 3 laboratory abnormalities in 3, and grade 4 laboratory abnormalities in 1; none of the adverse events or abnormalities were judged to be treatment related. In an-intent-to-treat analysis, an HIV-1 RNA level <400 copies/mL at week 144 was achieved in 43% (10 of 23 participants; 95% confidence interval, 23.2%-65.5%); in addition, 35% (8 of 23; 16.4%-57.3%) had an HIV-1 RNA level <50 copies/mL. Nine participants (39%) discontinued study treatment before 144 weeks, but none because of adverse events or drug intolerance. All participants with sustained virologic control had excellent adherence; most who experienced virologic failure had adherence levels <90%. HIV-1 genotypic drug resistance testing was available at time of failure from 6 participants; 1 had evolution in integrase resistance with E138T, S147G, and R263K mutations at week 192 and phenotypic dolutegravir resistance of a 5.1-fold change. CONCLUSIONS: Dolutegravir plus an optimized background regimen seemed safe, well tolerated, and efficacious in this cohort of treatment-experienced HIV-1-infected adolescents. Adherence remains problematic in this population. CLINICAL TRIALS REGISTRATION: NCT01302847.
BACKGROUND: P1093 is an ongoing phase I/II multicenter open-label study of dolutegravir plus an optimized background regimen in age-defined pediatric cohorts; here we report the long-term safety and virologic efficacy outcomes for the oldest cohort. METHODS: The study enrolled human immunodeficiency virus type 1 (HIV-1)-infected treatment-experienced adolescents aged 12 to <18 years, with an HIV-1 RNA level ≥1000 copies/mL . Cumulative safety and HIV-1 RNA outcomes were assessed once the last enrolled participant reached 144 weeks of follow-up. RESULTS: Among 23 adolescents enrolled, 16 remained in the study at least 144 weeks; the median follow-up was 153 weeks (range, 55-193 weeks). Dolutegravir was well tolerated, with grade 3 clinical adverse events in 5 participants, grade 3 laboratory abnormalities in 3, and grade 4 laboratory abnormalities in 1; none of the adverse events or abnormalities were judged to be treatment related. In an-intent-to-treat analysis, an HIV-1 RNA level <400 copies/mL at week 144 was achieved in 43% (10 of 23 participants; 95% confidence interval, 23.2%-65.5%); in addition, 35% (8 of 23; 16.4%-57.3%) had an HIV-1 RNA level <50 copies/mL. Nine participants (39%) discontinued study treatment before 144 weeks, but none because of adverse events or drug intolerance. All participants with sustained virologic control had excellent adherence; most who experienced virologic failure had adherence levels <90%. HIV-1 genotypic drug resistance testing was available at time of failure from 6 participants; 1 had evolution in integrase resistance with E138T, S147G, and R263K mutations at week 192 and phenotypic dolutegravir resistance of a 5.1-fold change. CONCLUSIONS:Dolutegravir plus an optimized background regimen seemed safe, well tolerated, and efficacious in this cohort of treatment-experienced HIV-1-infected adolescents. Adherence remains problematic in this population. CLINICAL TRIALS REGISTRATION: NCT01302847.
Authors: A Mocroft; B Ledergerber; C Katlama; O Kirk; P Reiss; A d'Arminio Monforte; B Knysz; M Dietrich; A N Phillips; J D Lundgren Journal: Lancet Date: 2003-07-05 Impact factor: 79.321
Authors: François Raffi; Hans Jaeger; Eugenia Quiros-Roldan; Helmut Albrecht; Elena Belonosova; Jose M Gatell; Jean-Guy Baril; Pere Domingo; Clare Brennan; Steve Almond; Sherene Min Journal: Lancet Infect Dis Date: 2013-09-25 Impact factor: 25.071
Authors: Sharon L Walmsley; Antonio Antela; Nathan Clumeck; Dan Duiculescu; Andrea Eberhard; Felix Gutiérrez; Laurent Hocqueloux; Franco Maggiolo; Uriel Sandkovsky; Catherine Granier; Keith Pappa; Brian Wynne; Sherene Min; Garrett Nichols Journal: N Engl J Med Date: 2013-11-07 Impact factor: 91.245
Authors: Neil Thivalapill; Tandzile Simelane; Nobuhle Mthethwa; Sandile Dlamini; Bhekumusa Lukhele; Velephi Okello; H Lester Kirchner; Anna M Mandalakas; Alexander W Kay Journal: Clin Infect Dis Date: 2021-08-02 Impact factor: 9.079
Authors: Cindy Vavro; Theodore Ruel; Andrew Wiznia; Nicole Montañez; Keith Nangle; Joseph Horton; Ann M Buchanan; Eugene L Stewart; Paul Palumbo Journal: Antimicrob Agents Chemother Date: 2021-10-25 Impact factor: 5.938
Authors: Johan Lombaard; Francis Ssali; Puthanakit Thanyawee; Jan Fourie; Simon Vanveggel; Cornelia Linthicum; Veerle Van Eygen; Rodica Van Solingen-Ristea Journal: Antimicrob Agents Chemother Date: 2021-12-06 Impact factor: 5.191